In Vivo Neuroprotective Properties and Action Mechanism(s) of Plant-produced Asialo-erythropoietin

摘要 迫切需要开发神经保护药物来预防或/和保护神经细胞。 脑缺血/再灌流、缺氧或细胞毒性物质引起的损伤和死亡。植物- 基于表达系统的重组人促红细胞生成素可用于生产非造血药 不含唾液酸的重组人促红细胞生成素衍生物可用于神经保护 用于预防和保护脑缺血/再灌注损伤的药物。在我们之前的 研究发现，植物来源的asialo-rhuEPO(asialo-rhuEPOP)是非红系的， 在幼年小鼠大脑中动脉模型中显示出良好的神经保护作用 闭塞(MCAO)I/R损伤。我们之前的研究已经为目前提出的 研究活动。在这个SC1续订申请中，我们建议扩展asialo-rhuEPOP介导的 对老年小鼠的神经保护研究，评估年轻和年轻小鼠的长期神经结果 并进一步了解其神经保护机制。

Abstract There is an acute need to develop neuroprotective drugs to prevent or/and protect neuronal cell damage and death caused by ischemia/reperfusion, hypoxia or cytotoxic agents in the brain. Plant- based expression system can be used to produce asialo-rhuEPO, a non-hematopoietic recombinant human EPO derivative lacking sialic acid, which could be used as a neuroprotective agent for preventing and protecting brain damage from ischemia/reperfusion injury. In our previous studies, we found that plant-produced asialo-rhuEPO (asialo-rhuEPOP) is non-erythropoietic and displays excellent neuroprotective effects in a young mouse model of middle cerebral artery occlusion (MCAO) I/R injury. Our previous studies have set the stage for the current proposed research activities. In this SC1 renewal application, we propose to extend asialo-rhuEPOP-mediated neuroprotection studies to aged mice, evaluate long-term neurological outcomes in both young and aged mice, and further understand its neuroprotective mechanisms.